# 2026-06722: FDA Hands Fast-Track Voucher for Kid's Rare Liver Fix

2026-06722, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-07; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-06722
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-06722
- Title: Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 17660
- Published: 2026-04-07
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Hands Fast-Track Voucher for Kid's Rare Liver Fix

## Summary

The FDA just gave a special fast-track ticket called a Priority Review Voucher to Immedica Pharma AB for their rare pediatric disease drug, LOARGYS, approved in February 2026. This voucher helps speed up future drug reviews, benefiting patients with rare diseases and encouraging companies to develop more treatments. It’s a big win for kids with Arginase 1 Deficiency and could speed up new medicines hitting the market.

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that LOARGYS (pegzilarginase-nbln), approved February 23, 2026, manufactured by Immedica Pharma AB, meets the criteria for a priority review voucher.

## Effects PRIA read

- New FDA Approval for ARG1‑D: benefit, high. The FDA approved LOARGYS (pegzilarginase-nbln) on February 23, 2026 to treat hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency. The drug is indicated to be used in conjunction with dietary protein restriction.
- Priority Review Voucher Issued: benefit, medium. The FDA issued a Priority Review Voucher to the sponsor, Immedica Pharma AB, tied to the approval of LOARGYS on February 23, 2026. The award is made under section 529 of the Federal Food, Drug, and Cosmetic Act to sponsors of approved rare pediatric disease product applications that meet certain cr…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-06722 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/07/2026-06722/issuance-of-priority-review-voucher-rare-pediatric-disease-product-loargys-pegzilarginase-nbln)
- [2026-06722 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-07/pdf/2026-06722.pdf)

## Related
- [Previous: 2026-06721, Caribbean Fishery Management Council 189th Public Hybrid Meeting](https://policyrisk.com/federal-register/2026-06721)
- [Next: 2026-06723, Notice of OFAC Sanctions Actions](https://policyrisk.com/federal-register/2026-06723)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-06722 (as of 2026-06-08).
